Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: Corcept Therapeutics’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050613
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Stock-based compensation | 52,459 | 40,853 |
| Accretion of marketable securities, net | (1,543) | (3,005) |
| Depreciation and amortization | 1,461 | 931 |
| Deferred income taxes | (10,229) | (31,469) |
| Changes in operating assets and liabilities: | ||
| Trade receivables | (17,134) | (10,591) |
| Inventory | (7,536) | (4,021) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Corcept Therapeutics's D&A?
- Corcept Therapeutics (CORT) reported D&A of $863K in Q2 2026.
- How has Corcept Therapeutics's D&A changed year-over-year?
- Corcept Therapeutics's D&A increased by 201.7% year-over-year, from $286K to $863K.
- What is the long-term trend for Corcept Therapeutics's D&A?
- Over 4 years (2021 to 2025), Corcept Therapeutics's D&A has grown at a 1.7% compound annual growth rate (CAGR), from $1.07M to $1.15M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Corcept Therapeutics's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude